Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis

This study aims to evaluate the effectiveness and safety of Bactorinol® nasal spray, a medical device containing winterized Pistacia lentiscus oil, in adults with vasomotor rhinitis. Vasomotor rhinitis is a chronic condition characterized by nasal congestion, rhinorrhea, and impaired nasal airflow. In this multicenter, prospective, randomized, controlled clinical trial, 100 adult participants will be assigned in a 1:1 ratio to receive either Bactorinol® nasal spray or isotonic saline solution for 20 consecutive days. The primary objective is to determine whether Bactorinol® improves nasal airflow, measured by Peak Nasal Inspiratory Flow (PNIF). Secondary objectives include evaluating changes in symptoms and quality of life using the SNOT-22 questionnaire, assessing nasal cytology, and monitoring treatment compliance and adverse events. The results of this study may help identify a non-pharmacological, natural-extract-based treatment option for patients with vasomotor rhinitis.

NCT Number	NCT07266688
Lead Sponsor	Liaquat University of Medical & Health Sciences Collaborators: University of Urbino "Carlo Bo"
Conditions	Vasomotor Rhinitis
Enrollment	120 participants
Start Date	2025-12-01
Primary Completion	2026-04-20 (estimated)
Study Completion	2026-04-20 (estimated)
Updated on ClinicalTrials.gov	2026-04-23